Anthony Emmer, DO
Neurology · Southfield, MINPI 1003819897
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AbbVie at 41.2% of the total. Reporting peaked in 2022 at $53,528 and has fallen 71.6% since, to $15,226 in 2025. Among neurology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,462 payments — averaging $70.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$71K
- Impel Pharmaceuticals Inc.$35K
- Sanofi$16K
- Pfizer$9K
- EMD Serono, Inc.$5K
- Novartis$4K
- plus $33K from 54 others
What the payments were for
- Consulting fees$36,78721%
- Speaking & faculty fees$88,46551%
- Travel & lodging$2,1491%
- Food & beverage$45,32426%
- Education$4450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$173,170 in reported general payments places this provider in the 90th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 16 | $499,417 |
| Kesimpta PenOfatumumab | 33 | $317,655 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 26 | $190,842 |
| VumerityDiroximel Fumarate | 18 | $158,643 |
| UbrelvyUbrogepant | 94 | $129,395 |
| PlegridyPeginterferon Beta-1a | 14 | $115,377 |
| Teriflunomide | 40 | $109,334 |
| ZeposiaOzanimod Hydrochloride | 11 | $92,789 |
| CopaxoneGlatiramer Acetate | 14 | $81,648 |
| Nurtec OdtRimegepant Sulfate | 52 | $70,637 |
| AustedoDeutetrabenazine | 13 | $62,955 |
| GocovriAmantadine Hcl | 20 | $54,359 |
| Emgality PenGalcanezumab-Gnlm | 54 | $52,247 |
| Aimovig AutoinjectorErenumab-Aooe | 50 | $40,421 |
| QuliptaAtogepant | 35 | $38,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga, Nurtec Odt | $8,689 | $570,05468 claims |
| BiogenVumerity, Plegridy | $3,414 | $274,02032 claims |
| AbbVieUbrelvy, Qulipta | $71,309 | $167,500129 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone, Austedo | $2,278 | $144,60327 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $323 | $92,78911 claims |
| MDD US Operations, LLCGocovri | $332 | $54,35920 claims |
| UCB, Inc.Briviact | $2,634 | $34,12918 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $247 | $28,00516 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $281 | $27,44781 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $574 | $19,20811 claims |
| AstraZenecaBrilinta | $1,424 | $9,29916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 652 neurology providers in Michigan.
Other neurology in Southfield
- Lawrence EilenderSouthfield$73K
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Wade CooperAnn Arbor$991K
- Bisena BulicaDetroit$900K
- Julie BurnhamMount Clemens$836K
- Amit MasihOkemos$785K
- Martin BelkinFarmington Hills$712K
- Robert PaceOwosso$693K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.